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Edited by Masayuki MiyasakaAbstract The mucosal epithelium secretes a variety of antimi-
crobial peptides that act as part of the innate immune system
to protect against invading microbes. Here, we describe the func-
tional properties of human defensin (HD) 5, the major antimicro-
bial peptide produced by Paneth cells in the ileum, in relation to
its structure. The antimicrobial activity of HD-5 against Esche-
richia coli proved to be independent of its structure, whereas the
unstructured peptide showed greatly reduced antimicrobial activ-
ity against Staphylococcus aureus. We ﬁnd that HD-5 binds to
the cell membrane of intestinal epithelial cells and induced secre-
tion of the chemokine interleukin (IL)-8 in a concentration- and
structure-dependent fashion. Incubation of HD-5 in the presence
of tumor necrosis factor alpha further increased IL-8 secretion
synergistically, suggesting that HD-5 may act as a regulator
of the intestinal inﬂammatory response.
Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Interleukin 8; TNF-a1. Introduction
Epithelial cells of the mucosa form a barrier between the gut
lumen and underlying host tissues. In addition to this barrier
function, epithelial cells perform a key role in host innate
and adaptive responses, secreting of a wide range of immuno-
modulatory molecules [1,2]. Paneth cells are specialized ileal
epithelial cells located at the crypt base in close vicinity of mul-
tipotent stem cells and fulﬁll a crucial role in innate immunity.
They are a source of several antimicrobial enzymes such as
lysozyme and group IIA phospholipase A2 (PLA2) as well as
the antimicrobial peptides human defensin 5 and 6 (HD-5
and HD-6), which are stored in secretory granules [3,4].
Defensins are small, cationic peptides with a characteristic b-
sheet-rich structure stabilized by three internal disulﬁde bonds
[5]. Based on the connectivity of the six cysteine residues,
human defensins are classiﬁed into a and b subfamilies [6–8].
In humans, six a-defensins have been described: HD-5 and
HD-6 and the human neutrophil peptides 1–4 (HNP1–4) ex-
pressed predominantly in neutrophils and natural killer cellsAbbreviations: HD, human defensin; HNP, human neutrophil peptide;
IL, interleukin; TNF, tumor necrosis factor
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doi:10.1016/j.febslet.2006.12.036[9]. Both the a- and b-defensin gene families evolved from an
ancestral b-defensin gene and distinct clusters of both families
are found adjacent on the chromosomal maps of all mammals
expressing a- and b-defensins [10,11].
Murine intestinal epithelium expresses at least 20 isoforms of
a-defensins, termed cryptdins [12,13]. Procryptdins are pro-
cessed to mature peptides by the matrix metalloproteinase
matrilysin, which is co-expressed within the Paneth cell secre-
tory granules [14]. In contrast, HD-5 is stored in its pro-form
and is further processed to the mature peptide after secretion.
Pro-forms of HD-5 can be processed in vitro by trypsin, which
is also expressed in Paneth cells [15]. In addition to their anti-
microbial properties, defensins have chemokine-like activities
[16]. Members of both a- and b-defensins act as chemotactic
attractants for human monocytes and subsets of dendritic cells
and T cells [17,18], however, their eﬀect on intestinal epithelial
cells is not very well characterized. Here, we examine the anti-
bacterial activity and the interaction with intestinal epithelial
cells of HD-5 in relation to its structure.2. Materials and methods
2.1. Materials
Chemicals used for solid phase peptide synthesis were obtained as
described [19]. Escherichia coli ATCC 25922 and Staphylococcus aureus
ATCC 29213 were from Microbiologics (St. Cloud, MN). Caco-2 cell
line was obtained from the American Type Culture Collection (Manas-
sas, VA).
2.2. Solid phase peptide synthesis
Chemical synthesis of HD-5 and HD-5Abu, a linear, unstructured
form of HD-5 in which the six cysteine residues are replaced by iso-
steric a-aminobutyric acid (Abu) was carried out as described [19].
Folding of HD-5 was carried out as described [19]. The molecular mass
of the peptides was veriﬁed by electrospray ionization mass spectrom-
etry (ESI-MS) as described previously [19]. 5-Carboxyltetramethyl-
rhodamine (Molecular Probes, Eugene, OR) was coupled to HD-5 as
follows: 2.0 mg HD-5 was dissolved in 1.0 ml 0.1 M NaHCO3, pH
8.3, 0.2 ml of 5-carboxyltetramethylrhodamine (10 mg/ml in DMSO)
and 40 ll di-isopropyl-ethylamine (DIEA) were then added. After stir-
ring for 2 h at room temperature, the reaction mixture was ﬁltered and
puriﬁed by reverse phase HPLC. The molecular mass was veriﬁed by
ESI-MS as described above.
2.3. Antibacterial activity assay
The antibacterial activity of HD-5 and HD-5Abu against E. coli
ATCC 25922 and S. aureus ATCC 29213 was carried out in a 96-well
turbidimetric assay as described previously [20].
2.4. Evaluation of IL-8 secretion by Caco-2 cells
Subconﬂuent monolayers of Caco-2 cells were maintained in RPMI
1640medium (Gibco), supplementedwith 10%FBS (Valley Biomedical,European Biochemical Societies.
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burg, MD), 20 mM HEPES, 1· nonessential amino acids, 1 mM
sodium pyruvate and 5% penicillin/streptomycin (Sigma) in a
humidiﬁed incubator at 37 C with 5% CO2. Caco-2 cells were used
between passages 35 and 42. Caco-2 cells were plated at a density of
4 · 104 cells/cm2 in a 96-well plate 48 h before use. The cells were
gently washed twice with serum-free medium and incubated for a fur-
ther 18 h in serum-free medium containing the peptides at a ﬁnal con-
centration of 50 or 100 lg/ml. In the presence of serum, the induction
of IL-8 secretion was not observed (not shown). Human recombinant
tumor necrosis factor alpha (Sigma; 100 ng/ml) was included during
incubation with the peptides (100 lg/ml) as indicated. The culture
supernatant was collected for measurement of IL-8 using the Lum-
inex-100 system (Bio-rad Laboratories).
2.5. Confocal Microscopy
Caco-2 cells (104 cells) were cultured on glass cover slips as described
above for 24–48 h. The cells were washed twice in serum-free medium
and incubated with rhodamine-HD5 (10 lg/ml) for 3 h. After incuba-
tion, cells were washed twice with Hanks’ balanced salt solution
(HBSS). The localization of rhodamine-HD5 on Caco-2 cells was visu-
alized using a Zeiss Laser Scanning Microscope (LSM) 510 system
(Carl Zeiss MicroImaging Inc., Thornwood, NY). Fluorescence was
excited using a helium–neon laser (543 nm). Emission was passed
through a 560 nm long-pass ﬁlter prior to acquisition. Optical sections
were 1 lm thick.3. Results
3.1. Chemical synthesis of HD-5 peptides
The HD-5 structure involves three intra-molecular disulﬁde
bonds [19]. To determine the structure of HD-5 in relation
to its function, a HD-5 derivative peptide was synthesized, inRetention time (min)
5 10 15 25 3020
0.4
0.3
0.2
0.1
0
A
bs
or
ba
nc
e 
at
 2
14
 n
m
R
el
at
iv
e 
in
te
ns
ity
 (%
)
20
0
40
60
80
100
Mass/Z (Da)
500 700 900 1100 1300
+5
+4
+3
3582.0±0.5
HD-5
Fig. 1. Folded and puriﬁed HD-5 and HD-5Abu analyzed by reversed phase
ionization mass spectrometry (ESI-MS). The HPLC analysis was carried ou
TFA; solvent B: acetonitrile + 0.1% TFA) at a ﬂow rate of 1 ml/min over 30 m
the expected values based on calculations of the average isotopic compositiowhich the six cysteine residues were replaced with L-a-amino-
butyric acid (HD-5Abu), thus preventing the formation of
disulﬁde linkage while leaving the peptide sequence otherwise
unaltered. Folded and puriﬁed HD-5 and puriﬁed HD-5Abu
were analyzed on C18 RP-HPLC (Fig. 1A and B). HD-5
was less hydrophobic than HD-5Abu, as indicated by their
relative retention time on C18 RP-HPLC. The molecular mass
of both peptides was conﬁrmed by ESI-MS (Fig. 1C and D).
The observed molecular masses of 3582.0 ± 0.5 Da for HD-5
and 3480.7 ± 0.3 Da for HD-5Abu agree with the calculated
average isotopic values of 3582.2 and 3480.2 Da, respectively.
3.2. Antimicrobial activity of HD-5 peptides
The antimicrobial activity of both peptides was examined
against E. coli ATCC 25922 and S. aureus ATCC 29213
(Fig. 2A). As described previously [20], HD-5 eﬃciently killed
both bacterial strains and, at comparable peptide concentra-
tion, proved more toxic towards S. aureus as compared to
E. coli. At the highest peptide concentration tested (125 lg/
ml), S. aureus appeared unable to recover from the 2 h incuba-
tion with HD-5. HD-5Abu was comparable to HD-5 in anti-
microbial activity towards E. coli, and was even slightly
more eﬃcient in killing at higher concentrations. Surprisingly,
killing of S. aureus by HD-5Abu was 4–5 orders of magnitude
less eﬃcient than killing by HD-5 at comparable peptide con-
centration.
To evaluate the salt dependence of HD-5 bacterial killing,
the antimicrobial assay was performed at increasing sodium
chloride concentrations (Fig. 2B). For these experiments, a
ﬁxed peptide concentration of 100 lg/ml was used againstRetention time (min)
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Fig. 2. (A) Survival curves of Escherichia coli ATCC 25922 (left) and Staphylococcus aureus ATCC 29213 (right) exposed to HD-5 (ﬁlled symbols) or
HD-5Abu (open symbols). Strains were exposed to the peptides at concentrations varying twofold from 0.12 to 125 lg/ml. (B) Strains were exposed
to ﬁxed peptide concentrations (100 lg/ml for E. coli; 50 lg/ml for S. aureus) in the absence or presence of the indicated concentrations of sodium
chloride. Each curve is the mean of three separate experiments. Points scored as zero survival could not be plotted.
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tration reduced the antimicrobial activity of HD-5. At the
highest salt concentration tested (100 mM), HD-5 was still sig-
niﬁcantly toxic against S. aureus, whereas antibacterial activity
against E. coli was almost completely inhibited, even at twice
the concentration of peptide. Against E. coli, the bactericidal
activity of HD-5Abu was signiﬁcantly inhibited only at a con-
centration of 50 mM NaCl, inhibition was not increased fur-
ther by higher salt concentration. Against S. aureus, the
antibacterial activity of HD-5Abu was completely inhibited
even at low salt concentrations. Taken together, these data
indicate that eﬀective killing of E. coli by HD-5 is structure-
independent or alternatively, more sequence-driven. Eﬃcient
activity against S. aureus requires the peptide to be folded
and was less inhibited by increasing salt concentrations.
3.3. Interaction of HD-5 peptides with intestinal epithelial cells
To examine the interaction of HD-5 with Caco-2 cells, rho-
damine-labeled HD-5 was synthesized. The molecular mass of
the puriﬁed peptide was veriﬁed by ESI-MS to be
3994.6 ± 0.6 Da, in good agreement with the calculated value
of 3994.2 Da (not shown). Following incubation of Caco-2
cells with the labeled peptide, localization of HD-5 was visual-
ized by ﬂuorescence confocal microscopy (Fig. 3). While local-
ization of HD-5 was predominantly seen at the surface of the
Caco-2 cells, internalization of the probe was also observed.
To test whether HD-5 induces an intestinal inﬂammatory re-
sponse, Caco-2 intestinal epithelial cells were incubated in thepresence of increasing concentrations of the peptide. Steady-
state quantities of secreted HD-5 have been estimated to be
in the range of 50–250 lg/ml in the intestinal lumen [4,15].
Therefore, we examined the eﬀects of the peptides at concen-
trations of 50 and 100 lg/ml. Cells incubated with 100 ng/ml
tumor necrosis factor a (TNF-a) were used as a positive con-
trol. HD-5 induced IL-8 secretion in a dose-dependent fashion
(Fig. 4, white bars). IL-8 levels increased 10-fold at a peptide
concentration of 100 lg/ml compared to control cells, similar
to IL-8 levels observed after incubation with TNF-a (Fig. 4,
grey bar). To examine the eﬀect of peptide structure, cells were
incubated with the same concentration of the HD-5Abu pep-
tide. Induction of IL-8 secretion was not observed in the pres-
ence of HD-5Abu at the same concentrations (Fig. 4, black
bars), indicating the induction of IL-8 secretion depends on
the structure of HD-5.
In addition to HD-5, TNF-a is also expressed by Paneth
cells [3]. Therefore, we examined the IL-8 secretion upon co-
incubation of intestinal epithelial cells with HD-5 and TNF-
a (Fig. 5). Incubation with HD-5 or TNF-a alone increased
IL-8 secretion 10-fold relative to the control. Co-incubation
of HD-5 and TNF-a resulted in an additional 6-fold increase
in IL-8 secretion as compared to the levels observed when
the two agents were applied separately. In contrast, HD-
5Abu was completely ineﬀective in stimulating IL-8 secretion.
Together, these data suggest that HD-5 and TNF-a enhance
IL-8 secretion by intestinal epithelial cells synergistically, and
that HD-5 must be structured to stimulate secretion.
Fig. 3. Confocal laser scanning microscopy images of Caco-2 cells incubated with rhodamine-HD-5. Cells were incubated in serum-free RPMI
medium for 3 h with 10 lg/ml of the peptide and were gently washed twice with HBSS prior to imaging. Left panels show the bright ﬁeld image,
middle panels show the ﬂuorescence image of the rhodamine-labeled peptide, and right panels are a superposition of the two images. The ﬂuorescence
image is a 1-lm optical section acquired approximately at the equator of the largest cells, which are typically 14–15 lm in thickness. Filled
arrowheads indicate examples of surface labeling; open arrowheads indicate examples of internalization.
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Fig. 4. IL-8 secretion by Caco-2 cells in the absence (light grey bar) or
presence of HD-5 (white bars) or HD-5Abu (black bars) at ﬁnal
concentrations of 50 or 100 lg/ml. TNF-a (100 ng/ml; dark grey bar)
served as a positive control. Following incubation for 18 h, culture
supernatants were analyzed for IL-8 using the Luminex-100 system in
duplicate. Data represent mean and standard deviation of three
individual experiments.
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Fig. 5. IL-8 secretion by Caco-2 cells in the presence of HD-5 (100 lg/
ml; white bars) or HD-5Abu (100 lg/ml; black bars), with and without
TNF-a (100 ng/ml) as indicated. No peptides (c) and TNF-a alone
(dark grey bar) served as controls. Following incubation for 18 h,
culture supernatants were analyzed for IL-8 using the Luminex-100
system in duplicate. Data represent mean and standard deviation of
three individual experiments.
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The role of antibacterial peptides in mucosal biology and in
particular how they link innate to adaptive immunity has
gained increasing interest. Several studies show that both the
alpha and the beta subfamilies of defensins display immuno-
modulatory or chemotactic properties in addition to their anti-microbial activity. We investigated the antimicrobial activity
and the immunomodulatory properties of HD-5 in relation
to the structure of the peptide. Here, we ﬁnd that killing of
E. coli by HD-5 is independent of peptide structure, whereas
antimicrobial activity against S. aureus requires the native
structure. Strain-speciﬁc as well as defensin-speciﬁc activity
has been observed previously in bacterial killing assays. For
example, HD-5 appeared more eﬃcient in killing S. aureus
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whereas HNP1 and HNP2 were more eﬃcient in killing S. aur-
eus ATCC 25923 [20]. Interestingly, the antimicrobial activity
of human b-defensin 3 (HBD3) was aﬀected neither by rear-
ranging the cysteine connectivity of the molecule nor by linear-
ization of the peptide [21]. This variation in potency against
various bacterial strains including E. coli and S. aureus has
also been observed for murine cryptdins [12,22]. Most likely,
these diﬀerences reﬂect diﬀerences in the nature of interactions
between defensins and microbial membrane components pres-
ent in diﬀerent bacteria. One possibility is that, in the case of
HD-5, the interaction with for example lipopolysaccharide
(LPS), exclusively present in gram-negative organisms, is more
dependent on electrostatic interactions, and hence more sensi-
tive to increasing ionic strength.
We ﬁnd that HD-5 induces secretion of IL-8 by epithelial
cells in a structure-dependent manner. Furthermore, HD-5
and TNF-a act synergistically to induce secretion. Murine
cryptdin 3 was shown to induce secretion of IL-8 by a human
intestinal epithelial cell line [23], most likely through a recep-
tor-independent mechanism. Interestingly, the observed induc-
tion of IL-8 secretion was linked to the ability of cryptdin 3 to
form anion-conducting pores in mammalian membranes.
Cryptdin 4, which is unable to form pores in mammalian cells,
did not induce IL-8 secretion [23]. Whether HD-5 has the abil-
ity to form channels in mammalian membranes is not known.
However, at concentrations up to 100 lg/ml, HD-5 was not
cytotoxic against Caco-2 cells, whereas the pore-forming toxin
melittin did [24]. Chemotactic properties involving speciﬁc
interactions with receptors have been described for various
defensins. Both HBD-2 and -3 have been shown to bind specif-
ically with the chemokine receptor CCR6 [18,21]. More re-
cently, interactions between HBD3 and CXCR4 [25] as well
as between HBD-2 and Toll-like receptor 4 (TLR4) have been
described [26]. Given the increasing evidence that defensin
expression is regulated in part by Toll-like receptor mediated
pathways [27] and that chemotactic properties of HD5 have
not been described, it is tempting to speculate that the interac-
tion between HD-5 and epithelial cells we observe speciﬁcally
involves a member of the TLR family.
Recently, a speciﬁc deﬁciency of HD-5 was observed in pa-
tients with ileal Crohn’s disease, a chronic disease of the intes-
tine characterized by inﬂammation of the gut [28]. A number
of gene polymorphisms in several cellular receptors, including
tumor necrosis factor receptors, Toll-like receptor 4 and
NOD2/CARD15 have been found associated with this disease.
[29–31]. In particular, NOD2/CARD15 has been identiﬁed to
be tightly linked with susceptibility to Crohn’s disease
[32,33]. NOD2 is an intracellular receptor for the bacterial pep-
tidoglycan component muramyl dipeptide and is expressed in
Paneth cells [34]. Importantly, approximately one-third of
Crohn’s disease patients carry loss-of-function mutations in
NOD2/CARD15 and show a further reduced expression of
HD-5 [28]. These observations have led to the suggestion that
decreased levels of a-defensin secreted by Paneth cells weaken
the antimicrobial defense of the ileal mucosa [35]. Based on
these observations and on our results, we speculate that lower
levels of HD-5 observed in Crohn’s disease patients compared
to normal conditions may compromise the ability of the intes-
tinal epithelium to respond to immune challenges by weaken-
ing the antibacterial activity as well as by weakening the
immune response of the epithelium.Acknowledgements: Erin Gutierrez and Darryl A. Auston are grate-
fully acknowledged for expert technical assistance. This work was sup-
ported by the National Institute of Health Grants AI058939 and
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